Detalles de la búsqueda
1.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hematol Oncol
; 41(5): 848-857, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496298
2.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502609
3.
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Neoplasma
; 69(6): 1466-1473, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36591807
4.
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Ann Hematol
; 99(7): 1583-1594, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32506244
5.
Osteolytic bone lesions, hypercalcemia and paraprotein, but not a myeloma: case report and review of literature.
Vnitr Lek
; 66(5): 90-95, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32942878
6.
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Ann Hematol
; 98(8): 1961-1972, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31065733
7.
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Ann Hematol
; 97(4): 669-678, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29318369
8.
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Immunology
; 152(3): 357-371, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28685821
9.
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Hematol Oncol
; 38(3): 412-414, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323881
10.
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
Am J Hematol
; 94(1): E35-E37, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30370955
11.
Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry.
Front Oncol
; 12: 874462, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35646641
12.
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP.
EJHaem
; 1(1): 170-180, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35847728
13.
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
Bone Marrow Transplant
; 54(7): 1107-1114, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30459429
14.
Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia.
J Cancer
; 10(21): 5041-5048, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31602255
15.
The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.
Leuk Res
; 73: 29-38, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30195062
16.
Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
Leuk Lymphoma
; 57(5): 1094-103, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26293000
17.
Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
Leuk Lymphoma
; 56(8): 2350-6, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25426666
Resultados
1 -
17
de 17
1
Próxima >
>>